Psoriasis Research Review, Issue 58

In this issue:

Guselkumab vs secukinumab for moderate-to-severe psoriasis
Onset of action with IL-17 and IL-23 inhibitors
Prevalence of advanced liver fibrosis in severe psoriasis
Tildrakizumab continuous dosing, interruption, dose adjustments and switching
Factors predicting biologic drug persistence in psoriasis
Coronary artery disease in patients with psoriasis
Prolonged low-dose ciclosporin in an Asian population
Factors associated with patientreported importance of skin clearance
Adalimumab and phototherapy in the Vascular Inflammation in Psoriasis Trial
Narrowband UVB phototherapy for psoriasis/atopic dermatitis
5-years of brodalumab for moderateto-severe plaque psoriasis

Please login below to download this issue (PDF)

Subscribe